Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
— Leading telemedicine company expandsoffering with hormone-free birth control as GLP-1 medication usageincreases—
— Hello Alpha partnership boosts awarenessof and access to Phexxifor millions of women—
SANDIEGO, June 27, 2024 /PRNewswire/ -- Women'shealth innovator Evofem Biosciences, Inc. (OTCQB: EVFM) todayannounced a new market partnership with Hello Alpha, a telemedicinecompany with a medical team specifically trained for a woman'sunique needs, to offerPhexxi®(lactic acid,citric acid and potassium bitartrate), the non-hormonalprescription vagin*l gel FDA-approved to prevent pregnancy forthose who choose to use an on-demand method of birthcontrol.
Hello Alpha and Phexxi are changing the narratives aroundwomen's healthcare and offering solutions that complement GLP-1medications like Ozempic, Wegovy, Mounjaro and Zepbound. Thesemedications can potentially reduce the effectiveness of birthcontrol pills during specific intervals within the dosing cycle. Toensure continued pregnancy prevention, providers onHelloAlpha.comrecommend switching to a non-oral birth controlmethod orusing an additional non-hormonal birth controlmethod, like Phexxi, alongside oral contraceptives during thesetimes.
Reinforcing Hello Alpha's commitment to improving healthcare forwomen, Gloria Lau, Co-founder &CEO, says, "This partnership with Evofem helps us offera safeand effective birth control option for women, especially those onGLP-1s and others looking for hormone-free contraceptives."
"Women everywhere deserve access to Phexxi, a non-hormonal,on-demand contraceptive method that honors their personalpreferences and respects their health autonomy," said Evofem CEOSaundra Pelletier. "This partnershipbetween Evofem and Hello Alpha empowers women by offering them thatcrucial freedom of choice."
Phexxi is the first and only FDA-approved hormone-free,locally-actingcontraceptive gel. It is applied zero-to-60minutes before intercourse and works, without hormones, bymaintaining the natural vagin*l microbiome with a pH that isinhospitable to sperm as well as certain bacterial and viralpathogens.
Hello Alpha, which is available in 50 states plus D.C. andoffers virtual care for more than 100 conditions, continues tofulfill its mission to bring convenient, affordable, and accessiblemedical care, medications, and resources to its patients. To learnmore about Hello Alpha, pleasevisithttps://www.helloalpha.com/.
About Hello Alpha
Hello Alpha is a virtual care solution that specializes ininclusive, expert care for all by bridging the gaps in women'shealth. Through asynchronous messaging, a specially-trained team ofprimary care providers delivers whole-person care for more than 100conditions. at Hello Alpha, every patient partners with a dedicatedprovider who offers personalized, preventive care andevidence-based treatments at every visit. The virtual platformeliminates the most common barriers to healthcare with asynchronousmessaging that enables patients to get care at any time, fromanywhere, without the need for scheduling appointments, in-personvisits, or busy waiting rooms. Hello Alpha provides patient carenationwide at a demonstrably lower cost. Founded in 2017, HelloAlpha serves patients directly and through theiremployers.
About Evofem Biosciences
Evofem Biosciences, Inc., is commercializing innovative productsto address unmet needs in women's sexual and reproductive health.The Company's first FDA-approved product, Phexxi®(lactic acid, citric acid and potassium bitartrate), isahormone-free, on-demand prescription contraceptive vagin*lgel. It comes in a box of 12 pre-filled applicators and is applied0-60 minutes before each act of sex. Learn more atphexxi.comand evofem.com.
In December 2023, Evofem enteredinto a Merger Agreement with Aditxt, Inc.(Nasdaq: ADTX) underwhich Aditxt intends to acquire Evofem. The parties reinstated andamended the Merger Agreement, as amended, in May 2024, and are working to close thecontemplated transaction in the second half of 2024.
Phexxi® is a registered trademark of EvofemBiosciences, Inc.
Media Contacts
Kristen Mondshein
kristen@kmmcommunications.com
Amy Raskopf
Chief Business Development Officer
Evofem Biosciences, Inc.
media@evofem.com
Forward-Looking Statements
This press release includes "forward-looking statements," withinthe meaning of the safe harbor for forward-looking statementsprovided by Section 21E of the Securities Exchange Act of 1934, asamended, and the Private Securities Litigation Reform Act of 1995including, without limitation, statements regarding the likelihoodof success and anticipated timing to close the contemplated Aditxttransaction. You are cautioned not to place undue reliance on theseforward-looking statements, which are current only as of the dateof this press release. Each of these forward-looking statementsinvolves risks and uncertainties. Important factors that couldcause actual results to differ materially from those discussed orimplied in the forward-looking statements are disclosed in theCompany's SEC filings, including its Annual Report on Form 10-K forthe year endedDecember 31, 2023filed with the SEConMarch 27, 2024, Quarterly Report on Form 10-Q for the threemonths endedMarch 31, 2024filed with the SEConMay 12, 2024, and any subsequent filings. Allforward-looking statements are expressly qualified in theirentirety by such factors. The Company does not undertake any dutyto update any forward-looking statement except as required bylaw.
View original content to downloadmultimedia:https://www.prnewswire.com/news-releases/hello-alpha-partners-with-evofem-to-offer-phexxi-as-a-hormone-free-contraception-solution-on-its-platform-for-womens-healthcare-302183829.html
SOURCE Evofem Biosciences, Inc.
Copyright 2024 PR Newswire
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
Hello Alpha News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Hello Alpha Partners with Evofem to Offer Phexxi\u00ae as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare","short_text":" Hello Alpha Partners with Evofem to Offer Phexxi\u00ae as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare\nPR Newswire\nSAN DIEGO, June 27, 2024 \u2014 Leading telemedicine...","one_line_short_text":" Hello Alpha Partners with Evofem to Offer Phexxi\u00ae as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare\nPR Newswire\nSAN...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94111934\/hello-alpha-partners-with-evofem-to-offer-phexxi","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1719491760,"date":"Thu Jun 27, 2024 ","time":"8:36 AM (3 days ago)","full_date":"June 27, 2024 8:36 AM","post_time":"June 27 2024","article_id":94111934,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 424B3 - Prospectus [Rule 424(b)(3)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94046211\/form-424b3-prospectus-rule-424b3","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718395288,"date":"Fri Jun 14, 2024 ","time":"4:01 PM (2 weeks ago)","full_date":"June 14, 2024 4:01 PM","post_time":"June 14 2024","article_id":94046211,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94031839\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718224545,"date":"Wed Jun 12, 2024 ","time":"4:35 PM (3 weeks ago)","full_date":"June 12, 2024 4:35 PM","post_time":"June 12 2024","article_id":94031839,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form PRER14A - Preliminary Proxy Soliciting materials","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94008533\/form-prer14a-preliminary-proxy-soliciting-materi","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717794732,"date":"Fri Jun 07, 2024 ","time":"5:12 PM (3 weeks ago)","full_date":"June 7, 2024 5:12 PM","post_time":"June 07 2024","article_id":94008533,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form PRE 14A - Other preliminary proxy statements","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93945797\/form-pre-14a-other-preliminary-proxy-statements","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717014797,"date":"Wed May 29, 2024 ","time":"4:33 PM (1 month ago)","full_date":"May 29, 2024 4:33 PM","post_time":"May 29 2024","article_id":93945797,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93932617\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716890921,"date":"Tue May 28, 2024 ","time":"6:08 AM (1 month ago)","full_date":"May 28, 2024 6:08 AM","post_time":"May 28 2024","article_id":93932617,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93909245\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716409460,"date":"Wed May 22, 2024 ","time":"4:24 PM (1 month ago)","full_date":"May 22, 2024 4:24 PM","post_time":"May 22 2024","article_id":93909245,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93891688\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716236145,"date":"Mon May 20, 2024 ","time":"4:15 PM (1 month ago)","full_date":"May 20, 2024 4:15 PM","post_time":"May 20 2024","article_id":93891688,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Evofem Biosciences Announces Financial Results for the First Quarter of 2024","short_text":" Evofem Biosciences Announces Financial Results for the First Quarter of 2024\nPR Newswire\nSAN DIEGO, May 15, 2024 SAN DIEGO, May 15, 2024 \/PRNewswire\/ -- The company behind the hormone-free...","one_line_short_text":" Evofem Biosciences Announces Financial Results for the First Quarter of 2024\nPR Newswire\nSAN DIEGO, May 15, 2024 SAN DIEGO, May 15, 2024...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93855070\/evofem-biosciences-announces-financial-results-for","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715770200,"date":"Wed May 15, 2024 ","time":"6:50 AM (2 months ago)","full_date":"May 15, 2024 6:50 AM","post_time":"May 15 2024","article_id":93855070,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93838342\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715631321,"date":"Mon May 13, 2024 ","time":"4:15 PM (2 months ago)","full_date":"May 13, 2024 4:15 PM","post_time":"May 13 2024","article_id":93838342,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93806787\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715199321,"date":"Wed May 08, 2024 ","time":"4:15 PM (2 months ago)","full_date":"May 8, 2024 4:15 PM","post_time":"May 08 2024","article_id":93806787,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93795566\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715112944,"date":"Tue May 07, 2024 ","time":"4:15 PM (2 months ago)","full_date":"May 7, 2024 4:15 PM","post_time":"May 07 2024","article_id":93795566,"source_id":"edgar2","media_url":null,"press_release":true}],"All News": [{"headline":"Hello Alpha Partners with Evofem to Offer Phexxi\u00ae as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare","short_text":" Hello Alpha Partners with Evofem to Offer Phexxi\u00ae as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare\nPR Newswire\nSAN DIEGO, June 27, 2024 \u2014 Leading telemedicine...","one_line_short_text":" Hello Alpha Partners with Evofem to Offer Phexxi\u00ae as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare\nPR Newswire\nSAN...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94111934\/hello-alpha-partners-with-evofem-to-offer-phexxi","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1719491760,"date":"Thu Jun 27, 2024 ","time":"8:36 AM (3 days ago)","full_date":"June 27, 2024 8:36 AM","post_time":"June 27 2024","article_id":94111934,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 424B3 - Prospectus [Rule 424(b)(3)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94046211\/form-424b3-prospectus-rule-424b3","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718395288,"date":"Fri Jun 14, 2024 ","time":"4:01 PM (2 weeks ago)","full_date":"June 14, 2024 4:01 PM","post_time":"June 14 2024","article_id":94046211,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94031839\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718224545,"date":"Wed Jun 12, 2024 ","time":"4:35 PM (3 weeks ago)","full_date":"June 12, 2024 4:35 PM","post_time":"June 12 2024","article_id":94031839,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form PRER14A - Preliminary Proxy Soliciting materials","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/94008533\/form-prer14a-preliminary-proxy-soliciting-materi","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717794732,"date":"Fri Jun 07, 2024 ","time":"5:12 PM (3 weeks ago)","full_date":"June 7, 2024 5:12 PM","post_time":"June 07 2024","article_id":94008533,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form PRE 14A - Other preliminary proxy statements","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93945797\/form-pre-14a-other-preliminary-proxy-statements","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717014797,"date":"Wed May 29, 2024 ","time":"4:33 PM (1 month ago)","full_date":"May 29, 2024 4:33 PM","post_time":"May 29 2024","article_id":93945797,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93932617\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716890921,"date":"Tue May 28, 2024 ","time":"6:08 AM (1 month ago)","full_date":"May 28, 2024 6:08 AM","post_time":"May 28 2024","article_id":93932617,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93909245\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716409460,"date":"Wed May 22, 2024 ","time":"4:24 PM (1 month ago)","full_date":"May 22, 2024 4:24 PM","post_time":"May 22 2024","article_id":93909245,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93891688\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716236145,"date":"Mon May 20, 2024 ","time":"4:15 PM (1 month ago)","full_date":"May 20, 2024 4:15 PM","post_time":"May 20 2024","article_id":93891688,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Evofem Biosciences Announces Financial Results for the First Quarter of 2024","short_text":" Evofem Biosciences Announces Financial Results for the First Quarter of 2024\nPR Newswire\nSAN DIEGO, May 15, 2024 SAN DIEGO, May 15, 2024 \/PRNewswire\/ -- The company behind the hormone-free...","one_line_short_text":" Evofem Biosciences Announces Financial Results for the First Quarter of 2024\nPR Newswire\nSAN DIEGO, May 15, 2024 SAN DIEGO, May 15, 2024...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93855070\/evofem-biosciences-announces-financial-results-for","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715770200,"date":"Wed May 15, 2024 ","time":"6:50 AM (2 months ago)","full_date":"May 15, 2024 6:50 AM","post_time":"May 15 2024","article_id":93855070,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93838342\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715631321,"date":"Mon May 13, 2024 ","time":"4:15 PM (2 months ago)","full_date":"May 13, 2024 4:15 PM","post_time":"May 13 2024","article_id":93838342,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93806787\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715199321,"date":"Wed May 08, 2024 ","time":"4:15 PM (2 months ago)","full_date":"May 8, 2024 4:15 PM","post_time":"May 08 2024","article_id":93806787,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/aditxt-ADTX\/stock-news\/93795566\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715112944,"date":"Tue May 07, 2024 ","time":"4:15 PM (2 months ago)","full_date":"May 7, 2024 4:15 PM","post_time":"May 07 2024","article_id":93795566,"source_id":"edgar2","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More Hello Alpha News Articles
